The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) hit a new 52-week low and has $9.23 target or 12.00% below today’s $10.49 share price. The 8 months bearish chart indicates high risk for the $374.47 million company. The 1-year low was reported on Sep, 30 by Barchart.com. If the $9.23 price target is reached, the company will be worth $44.94M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 704,280 shares traded hands. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 40.53% since February 26, 2016 and is downtrending. It has underperformed by 50.95% the S&P500.
Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on November, 3. They expect $-0.74 EPS, up 9.76% or $0.08 from last year’s $-0.82 per share. After $-0.75 actual EPS reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -1.33% EPS growth.
Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage
Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The firm earned “Hold” rating on Wednesday, August 12 by Zacks. RBC Capital Markets downgraded the shares of DVAX in a report on Thursday, April 28 to “Sector Perform” rating. JP Morgan downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) rating on Wednesday, April 27. JP Morgan has “Neutral” rating and $22 price target. The company was initiated on Monday, November 30 by RBC Capital Markets.
According to Zacks Investment Research, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in Q2 2016. Its down 0.04, from 1.06 in 2016Q1. The ratio dived, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.
Wfg Ltd Partnership holds 0% or 65 shares in its portfolio. Howard Hughes Medical Institute last reported 0.1% of its portfolio in the stock. Falcon Point Limited Com accumulated 21,753 shares or 0.05% of the stock. California Pub Employees Retirement System has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Moreover, Alliancebernstein Lp has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 45,620 shares. Meeder Asset Management, a Ohio-based fund reported 7,331 shares. Polar Capital Llp accumulated 0.1% or 379,932 shares. Voya Investment Mgmt Llc last reported 16,941 shares in the company. Nationwide Fund has 0% invested in the company for 24,881 shares. Tekla Cap Mgmt Ltd Liability Company holds 0.21% or 345,050 shares in its portfolio. State Street last reported 1.57 million shares in the company. Sabby Limited Liability Company accumulated 290,505 shares or 0.22% of the stock. Citigroup reported 2,271 shares or 0% of all its holdings. The California-based Schwab Charles Mgmt Inc has invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Blackrock Inv Mngmt Ltd Liability Corp owns 147,646 shares or 0% of their US portfolio.
Insider Transactions: Since May 12, 2016, the stock had 2 insider buys, and 0 insider sales for $57,940 net activity. Janssen Robert bought $15,120 worth of stock or 1,000 shares. $42,820 worth of Dynavax Technologies Corporation (NASDAQ:DVAX) was bought by Gray Eddie on Friday, May 20.
More news for Dynavax Technologies Corporation (NASDAQ:DVAX) were recently published by: Investorplace.com, which released: “Dynavax Technologies Corporation (DVAX) Injected With 20%-Plus Gains” on September 06, 2016. Prnewswire.com‘s article titled: “Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” and published on September 06, 2016 is yet another important article.
DVAX Company Profile
Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.